Nova Pneuma

NovaPneuma is a Philadelphia-based biotechnology company focused on developing novel small molecule therapeutics for inflammatory and oxidative stress-related respiratory diseases. The company's lead candidate, LGM2605, is a synthetic analog of the flaxseed-derived lignan secoisolariciresinol diglucoside (SDG) that acts as a potent antioxidant, free radical scavenger, and anti-inflammatory agent. NovaPneuma primarily targets high-unmet-need conditions such as radiation-induced lung injury, chronic obstructive pulmonary disease (COPD), and malignant mesothelioma. By leveraging the Nrf2 signaling pathway, the company aims to provide protective and therapeutic benefits against environmental, occupational, and medical lung insults.